Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Carcinoma, Renal Cell · Human Immunodeficiency Virus (HIV) Infection

Merck KGaA, Darmstadt

Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt clinical programs — 63 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Frankfurter Str. 250, Darmstadt, 64293, DE HQ
7,364 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Frankfurter Str. 250, Darmstadt, 64293, DE
Employees
7,364
Programs
63
Drugs
50
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Merck KGaA, Darmstadt projects

63 ClinicalTrials.gov programs sponsored by Merck KGaA, Darmstadt.

Merck KGaA, Darmstadt has 63 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

63 programs

Clinical programs

Page 2 of 2

  1. Miransertib

    Merck KGaA, Darmstadt, Germany

    PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome

    phase 2 small molecule terminated

    1 trial

  2. Paclitaxel

    Merck KGaA, Darmstadt, Germany

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  3. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Advanced Non-Small Cell Lung Cancer

    phase 2 mab completed

    1 trial

  4. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Melanoma

    phase 2 mab completed

    1 trial

  5. Pembrolizumab (+) Berahyaluronidase alfa

    Merck KGaA, Darmstadt, Germany

    Squamous Cell Carcinoma

    phase 2 mab active

    1 trial

  6. Pembrolizumab 200 mg

    Merck KGaA, Darmstadt, Germany

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 mab active

    1 trial

  7. Pembrolizumab 200 mg

    Merck KGaA, Darmstadt, Germany

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  8. Pembrolizumab/Vibostolimab coformulation

    Merck KGaA, Darmstadt, Germany

    Metastatic Non Small Cell Lung Cancer

    phase 2 mab completed

    1 trial

  9. Raludotatug Deruxtecan (R-DXd)

    Merck KGaA, Darmstadt, Germany

    Gastrointestinal Cancer

    phase 2 mab active

    1 trial

  10. alvimopan

    Merck KGaA, Darmstadt, Germany

    Constipation

    phase 2 small molecule completed

    1 trial

  11. Boserolimab

    Merck KGaA, Darmstadt, Germany

    Pharmacokinetics

    phase 1 small molecule completed

    1 trial

  12. MSC2156119J

    Merck KGaA, Darmstadt, Germany

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  13. Bisoprolol

    Merck KGaA, Darmstadt, Germany

    Hypertension

    approved small molecule completed

    1 trial

  14. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Carcinoma, Non-Small-Cell Lung

    approved small molecule completed

    1 trial

  15. Raltegravir

    Merck KGaA, Darmstadt, Germany

    Human Immunodeficiency Virus (HIV) Infection

    approved small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Merck KGaA, Darmstadt have?

63 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.